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Abstract—The cloudUPDRS app is a Class I medical device,
namely an active transient non-invasive instrument, certified by
the Medicines and Healthcare products Regulatory Agency in
the UK for the clinical assessment of the motor symptoms of
Parkinson’s Disease. The app follows closely the Unified Parkin-
son’s Disease Rating Scale which is the most commonly used
protocol in the clinical study of PD; can be used by patients and
their carers at home or in the community; and, requires the user
to perform a sequence of iterated movements which are recorded
by the phone sensors. This paper discusses how the cloudUPDRS
system addresses two key challenges towards meeting essential
consistency and efficiency requirements, namely: (i) How to
ensure high-quality data collection especially considering the
unsupervised nature of the test, in particular, how to achieve
firm user adherence to the prescribed movements; and (ii) How
to reduce test duration from approximately 25 minutes typically
required by an experienced patient, to below 4 minutes, a
threshold identified as critical to obtain significant improvements
in clinical compliance. To address the former, we combine a
bespoke design of the user experience tailored so as to constrain
context, with a deep learning approach used to identify failures
to follow the movement protocol while at the same time limiting
false positives to avoid unnecessary repetition. We address the
latter by developing a machine learning approach to personalise
assessments by selecting those elements of the UPDRS protocol
that most closely match individual symptom profiles and thus
offer the highest inferential power hence closely estimating the
patent’s overall UPRDS score.
I. INTRODUCTION
Parkinson’s Disease (PD) is a degenerative neurological
condition associated with a wide spectrum of symptoms in-
cluding tremor, slowness of movement and freezing, swal-
lowing difficulty, sleep-related difficulties and psychosis [17].
Care for patients with PD involves the management of both
motor and non-motor symptoms as well as palliative care.
Since there is no cure, symptom management is a life-long
process that affects not only the patients but also their families
and carers. Clinical care pathways include pharmacological
treatment corresponding to the exact stage of the disease,
physiotherapy, and surgery [35]. As a result of medication with
L-Dopa, a key element of the typical pharmacological regime
for PD, patients are expected to develop side effects such as
dyskinesias [43]. Since symptoms vary greatly independently
of treatment and PD progresses at different rates in different
individuals, treatment requires regular clinical monitoring and
medication adjustment.
There are over 130,000 people with Parkinson’s in the UK,
each individual seen by a specialist doctor or nurse only once
or twice a year, allowing only brief and intermittent assessment
of the wide range of their motor and non-motor symptoms
[37]. This in turn limits opportunities to precisely quantify PD
progression and the effectiveness of patient stratification: the
restricted availability of data concerning individual variability
and actual symptom trends limits opportunities to adapt care
to the needs of a particular individual at a specific time. To
address this challenge we developed cloudUPDRS, the first
smartphone app to achieve certification as a Class I medical
device by the Medicines & Healthcare products Regulatory
Agency in the UK for the clinical assessment of the motor
symptoms of Parkinson’s.
cloudUPDRS augments standard clinical care pathways by
enabling daily assessments which lead to (i) more consistent
and reliable care, (ii) early identification of problems such
as medication side-effects, thus enabling earlier intervention,
(iii) monitoring of individualised patient trends leading to
more effective patient stratification, and (v) enable patients to
take ownership of their own care through non-pharmacological
measures such as improved nutrition and physical therapy.
The cloudUPDRS system is based on the Universal Parkin-
son’s Disease Rating Scale [14] and the PDQ39 questionnaire
[18], and incorporates a cloud-based Big Data management
and analytics service to generate objective and reliable assess-
ments of motor performance. Patients use the app at home
to record sensor measurements while performing a series of
simple actions with each limb, such as tapping the screen to
assess bradykinesia and holding the phone on their knee to
assess tremor. The data captured by the phone is then used to
calculate the clinical UPDRS score through the application of a
biomedical signal processing pipeline. Additional longitudinal
analytics are performed subsequently to enable trend analysis
and patient stratification.
This paper presents two recent developments within
cloudUPDRS, specifically:
• A deep learning technique applied to sensor observations
so as to assess compliance with the actions dictated by
the UPDRS protocol. Combined with a bespoke user
experience this technique can replace expert supervision
while maintaining high-quality data collection.
• Personalised tests reducing the time required to carry out
an assessment to less than 4 minutes. These so-called
quick tests are created using machine learning to select a
subset of UPDRS observations that closely estimate the
motor performance of a particular patient.
In the following section we review research related to this
work and then proceed to report on key factors for patient
compliance identified through user research in Section III. We
present the cloudUPDRS system in Section IV and in Section
V we report on certification. We then proceed to discuss the
details of the two techniques identified above in Sections VI
and VII correspondingly.
II. RELATED WORK
In [20], we demonstrate the feasibility of using smartphones
as a means to assess commonly occurring motor symptoms
of PD in a clinical setting. Specifically, we design, develop
and validate in a clinical study a prototype app on Android
implementing Part III of the MDS-UPDRS[14]. Using the
accelerometer and touch screen sensors commonly available
in modern smartphones, we are able to carry out hand and
leg tremor measurements, as well as gait and bradykinesia
assessments using finger tapping tasks to replicate the majority
of these tests (cf. Table I and Section IV-A). Other research
groups have followed a similar approach focusing on specific
symptoms. Most commonly tremor measurements are consid-
ered for example [9], [22], [25] and [26] all provide proof-of-
concept implementations of upper limb tremor estimation.
Two major projects by the M. J. Fox Foundation in the
US currently explore the diversity of PD motor symptoms
with a large population sample. The first employs the mPower
app (http://parkinsonmpower.org/) by Sage Bionetworks [41]
implemented using the open source researchkit framework
developed by Apple on iOS (http://researchkit.org/). The focus
of this work is to develop a large data set of motor per-
formance observations, which can be used as a benchmark
for the experimental evaluation of algorithms providing PD
diagnosis. The second project is in collaboration with Intel
and The Grove Foundation and employs wearables to provide
24×7 monitoring of PD patients—specifically a Pebble watch
(https://www.pebble.com/) to measure wrist tremor relayed via
an Android app to a Cloudera-based back end for storage and
analysis. The focus of this study is the development of a deep
longitudinal data set capturing in minute detail the second-by-
second variations of motor symptoms from a population of
tenths of thousands of volunteers. However, battery longevity
and data transmission issues have limited opportunities to
capture complete traces and the project is currently considering
alternative strategies.
Recently, the suitability of machine learning has been
investigated for the assessment of PD. Voice samples are
processed using standard machine learning algorithms in [2]
to correlate individual performance and MDS-UPDRS score. A
deep learning approach is adopted in [15] to identify patients
in ON and OFF states using Restricted Boltzmann Machines to
analyse accelerometer data. Both projects report encouraging
results which merit further investigation but current perfor-
mance limitations prevent these techniques from becoming an
effective clinical tool.
III. UNDERSTANDING PATIENTS WITH PD
The wider adoption of cloudUPDRS by patient communities
necessitates that tests are incorporated as part of their daily
routine. To understand how to best facilitate this we carried out
extensive interviews with clinicians, technologists, patients,
carers and patient advocates (22 individuals in total); a web
survey with participants from the research volunteer pool of
Parkinson’s UK receiving 166 unique submissions; and, three
audience panels (16 participants in total). Across all studies we
recruited participants with a confirmed diagnosis of PD and
excluded individuals with generic symptoms of Parkinsonism.
Patient participants represent all Hoehn & Yahr levels except
for the audience panels in which participation was limited to
Level 3, due to the practicalities of access to the venue.1
The potentially transformative role of smartphone apps
for PD was widely acknowledged in interviews. The ex-
pectation of positive outcomes was closely related to recent
trends enabling the direct involvement of patients in estab-
lishing research priorities, the use of patient expertise in
research, and towards greater transparency. This perspective
was often related to opportunities for patient empowerment
as expressed for example in online communities such as
PatientsLikeMe [8], suggesting that evidence-based care must
cater for the translation of evidence into practice in a manner
directly accessible to and understandable by patients.
We employed the web survey to explore current phone usage
patterns specifically among patients and to identify potential
constraints that may place barriers for the adoption of the
cloudUPDRS app. Responses received were primarily from
mobile phone users (96%) with 77% coming from those with
a smartphone. The majority of smartphone owners (87%) use
it daily with only 14% reporting significant difficulties. A
relative small proportion of those with smartphones (20%)
use apps to track their symptoms or manage medication.
The vast majority (86%) expects to make regular use of the
cloudUPDRS app with 64% expressing a preference for the
test session lasting a maximum of 5 minutes, 27% accepting a
test duration of 10 minutes, and 5% even longer. The majority
(68%) expect to make use of the app at least once per day to
assess their symptoms.
Audience panels combined elements of user experience
evaluation and a wider exploration of perceived costs and
benefits of the cloudUPDRS app, which was demonstrated
during the sessions. Panelists identified specific problems with
the version presented, for example the potential effects of
involuntary movements common to specific patient profiles
and suggested improvements. As relates to the utility of the
app and their motivation for regular use, the opportunity
to manage symptoms was an unequivocal benefit for the
majority of participants and strongly motivated their involve-
ment. However, access to detailed performance data was less
important compared to the sense of understanding afforded
1Hoehn & Yahr is a clinical rating scale that defines categories of motor
function in PD, ranging from minimal or no functional disability at level 1
to confinement to bed unless aided at Level 5.
Fig. 1. Views of the user interface of the cloudUPDRS app showing session management, tremor recording and finger tapping activities..
by the experience of using the app and thus of control over
the disease. All participants identified with the strong desire
to make a contribution towards combating the disease, and
considered their donation of personal data and their open
availability for research was seen as a means to achieve this
goal. As a consequence, no privacy concerns were expressed.
IV. THE CLOUDUPDRS SYSTEM AND APP
The complete cloudUPDRS system consists of:
1) A smartphone app for Android that enables patients
to carry out motor performance tests and complete a
wellness self-assessment; conduct session management;
and securely submit data to the cloudUPDRS service.
2) Cloud-based scalable data collection service that ingests
data from patients’ smartphones; ensures secure data
management; and applies the signal processing pipeline.
3) Data-mining toolkit for medical intelligence incorporat-
ing quantitative and semi-structured data, and longitudi-
nal analyses, clustering and classification; and a clinical
user interface incorporating visualisation.
The cloudUPDRS app implements a comprehensive work-
flow (partially depicted in Figure 1) that provides audio, video
and textual media to guide patients and their carers to conduct
the tests at home and in the community unsupervised by a
trained clinician or specialist nurse. The app implements a
bespoke user interaction design to ensure that the data recorded
capture the actual motor performance features as required
for the successful application of MDS-UPDRS. Specifically,
patients are guided through a carefully orchestrated sequence
of actions while the app records sensor measurements. By
requiring the execution of specific action sequences the app
restricts the degrees of freedom of individual movement and
thus imposes structure and disambiguates user context by
limiting the range of observed behaviours.2 As a result, the
2The action sequences can be seen in video demonstrations available at
http://www.updrs.net/help.
recorded signal can be interpreted accurately using a small set
of heuristics rather than require the use of a full context model
and reasoning approach [3]. Finally, the app automatically
adapts to match the specifications of its host device and
incorporates a delay tolerant service to manage data upload.
The full test administered by the cloudUPDRS app consists
of 17 individual observations, specifically kinetic, postural and
resting tremor for the left and right hand; left and right leg
agility and resting tremor; single and double target finger
tapping on both sides; and, gait. During each observation
period lasting 60 seconds, the patient is required to assume
a specific position and perform the prescribed movement as
described in the previous paragraph. Following the recording
of these observations the patient is presented with a question-
naire incorporating selected questions from the Parkinson’s
Disease Questionnaire (PDQ-39) [18] and recording the time
of the most recent medication intake.
The cloudUPDRS service is engineered to facilitate scalable
performance by adopting the microservices architecture [34].
This approach is set in contrast to traditional monolithic web
applications and aims to maximise opportunities for vertical
decomposition and scaling-out, which are critical for high
performance and service resilience in data intensive situations.
cloudUPDRS microservices are implemented as composite
Docker containers, are loosely coupled and employ lightweight
communication and coordination mechanisms such as the
Consumer-Driven Contract pattern. System componentization
is enforced via versioning of published RESTful interfaces and
sandboxed instances of the service can be deployed automat-
ically to cater for data isolation between distinct regulatory
domains. The overall service architecture has been designed
for scalability so that real-time streams captured for exam-
ple during concurrent patient consultations can be integrated
on the fly with archival information from the longitudinal
datastore service. To facilitate this modus operandi, we pro-
vide structured workflows implemented through microservices
TABLE I
ANALYTICS TOOLBOX SIGNAL PROCESSING FUNCTIONS AND
CORRESPONDENCE TO THE SECTIONS OF THE MDS-UPDRS.
Analytic Function MDS-UPDRS Section
Rest Tremor 3.17 (rest tremor amplitude)
Postural Tremor 3.15 (postural tremor of the hands)




movements of the hands)
Leg agility 3.8 (leg agility)
Finger tapping 3.3 (rigidity) & 3.4 (finger tapping)
Gait 3.10 (gait) & 3.11 (freezing of gait)
following the lambda architecture [30], which facilitates the
efficient fusion of real-time and archival data on the fly.
A. Bio-signal Processing
Precise assessment of tremor, bradykinesia and gait is
typically carried out using laboratory equipment for example
tailor-made biomedical data acquisition systems incorporating
transducers such as high-frequency/high-accuracy accelerom-
eters and gyroscopes, signal amplifiers and filters and high-
performance analog-to-digital converters. The captured signal
is analysed subsequently by specialist commercial software
such as Spike 2 by Cambridge Electronic Design Ltd with the
total cost of a complete system rising to tenths of thousands.
Laboratory based clinical rating however is constrained by
the requirement that the patient is present in the clinic, and in
practice can only be carried out as a “snap-shot” assessment. In
[20] we show that the sensor, clock and data acquisition hard-
ware of a low-end smartphone captures data with sufficient
accuracy to precisely quantify the magnitude of PD motor
symptoms across the majority of the tests included in Part
III of the MDS-UPDRS by comparing its performance against
results obtained using a biomedical analytics system by CED.
In cloudUPDRS we automate the methodology presented in
[20] as a bespoke cloud-based data analytics service [11]. For
completeness of presentation, we briefly summarise the main
features of this system here.
1) Tremor: Tremor measurements are recorded for both
hands at rest, at posture and in action as listed in Table I.
For rest tremor measurements, users are asked to relax their
hands on their lap in a supine position while the phone is lying
in their palm. For the postural tremor measurements patients
are guided to keep their arm outstretched directly on their
front while holding the smartphone. Finally, for action tremor
measurements they are required to hold the phone and move
it between the chest and the fully outstretched position on
their front. In all cases, acceleration is recorded along three
axes in m/s2 at the maximum supported sampling rate (at
least 50Hz) and timestamped at maximum resolution (typi-
cally microseconds). Tremor is calculated as the cumulative
magnitude of the scalar sum acceleration across three axes for
all frequencies between 2Hz and 10Hz. To obtain this power
spectrum the signal is first filtered with a Butterworth high-
pass second order filter at 2Hz and the Fast Fourier Transform
(FFT) is subsequently applied to the filtered waveform data.
2) Bradykinesia : MDS-UPDRS assess bradykinesia, or else
the slowness of movement, through three different factors: (i)
pronation-supination movements, (ii) leg agility, and (iii) fin-
ger tapping. In the first test patients are asked to hold the phone
and perform alternating pronation-supination movements, that
is rotating the palm of the hand toward the inside so that it is
facing downward and then toward the outside so that the palm
is facing upward, as fast and as fully as possible. Leg agility
measurements require the phone to be placed on the thigh of
the patient while seated, holding the phone lightly with the
ipsilateral hand, while raising and stomping the foot on the
ground as high and as fast as possible. During both tests the
phone is recording acceleration data in a manner similar to
the tremor tests. The assessment of the pronation-supination
movements and leg agility tests requires the estimation of the
frequency and power of movement. To obtain these, the toolkit
first removes DC and applies a Butterworth low-pass second
order filter at 4Hz in order to exclude most of the tremor.
Subsequently, the power of the movement is calculated as
the total amplitude between 0Hz and 4Hz and the frequency
derived from the power spectrum.
Finger tapping performance is assessed in two tests using
single and dual targets presented on the screen of the phone at
set locations with patients attempting to tap them as fast and
as accurately as possible (alternating between targets in the
dual-target case). When tapping accidentally occurs outside
the screen area the test is repeated. The touch-sensitive screen
of the smartphone is used to collect the information used for
performance calculations, specifically the timing of each touch
event, its duration, the direction of movement (upwards or
downwards), the coordinates on the phone screen, and the
amount of pressure applied are recorded. For the two-target
variant it is necessary that the distance between targets be
at a specific distance irrespective of the size of the screen
or of the device. To estimate finger tapping performance the
analytical functions first identify all touch events and employ
the associated timestamps to estimate tap frequency (taps
per second), the mean hand movement time between taps
(in milliseconds), and the actual movement distance between
alternative tapings in the dual-target case (in centimetres).
3) Gait: MDS-UPDRS assesses gait by considering multiple
behaviours including stride amplitude and speed, height of
foot lift and heel strike, and turning and arm swing [48].
The cloudUPDRS variant of this test requires the patient to
walk along a straight line for five meters, turn around and
return to the point of departure, while the smartphone is
positioned either in their belt or trousers pocket. Since it is
only possible to measure acceleration data from a single point
at the waistline we employ the techniques in [27], [28] to
estimate stride frequency and length, velocity and turning time.
V. CERTIFICATION
There are numerous wellness and self-tracking apps readily
available on all major platforms and many more that have been
developed for research. The vast majority of these apps do
not conform to the safety, quality, performance and regulatory
requirements set for medical devices and as such can only
be employed either to encourage a healthy lifestyle or for
research purposes correspondingly — but are not tools that
can be used to support medical diagnosis. This fact is often
explicitly reflected in their terms and conditions of use for
example, quoting from a popular Parkinson’s Disease app “we
cannot, and thus we do not, guarantee or promise that you will
personally receive any direct benefits.”
Medical devices are regulated and must conform to rules
enforced by regional legislation. Within the European Union,
harmonisation of regulations across member countries is facili-
tated by the Medical Devices Directive (MDD), which provide
the blueprint for country–specific legislation. Although the
MDD considers situations when software would be treated as
a medical device it does not explicitly examine smartphone
apps and so its provisions are open to interpretation, an issue
that we address in this section. Further, the MDD requires
that each member state establishes a Competent Authority to
provide guidance and enforce regulation of medical devices
and in the UK this responsibility lies with the Medicines and
Healthcare products Regulatory Agency (MHRA).
Under Article 1 Clause 2(a) of the MDD a medical device
is defined as “any instrument, apparatus, appliance, software,
material or other article, whether used alone or in combination,
including the software intended by its manufacturer to be
used specifically for diagnostic and/or therapeutic purposes.”
The current interpretation of this definition by the MHRA as
relating to apps implies that “if the [mobile] application is
intended to carry out further calculations, enhancements or
interpretations of entered/captured patient data, [· · · ] it will
be a Medical Device. If it carries out complex calculations,
which replaces the clinician’s own calculation and which will
therefore be relied upon, then it will certainly be considered
a Medical Device.” Hence, the features of the cloudUPDRS
app clearly place it within the provisions of the MDD. For
certification purposes, the named publisher of the app on
the selected platform store is considered its manufacturer as
defined by the MDD, and thus the party obliged to ensure
conformity with the provisions of the directive.
According to the MDD, the cloudUPDRS app is considered
a Class 1 medical device that is, an active transient non-
invasive instrument. Class 1 devices are considered lower risk
and as such as less closely regulated. In this case, certification
requires that the app meets the Essential Requirements defined
in Annex I of the MDD including evidence of software de-
velopment in compliance with ISO IEC 62304:2006. The app
must be supported by comprehensive documentation ensuring
that it can be used safely and appropriately by patients and its
publisher must “implement and maintain corrective action and
vigilance procedures” to ensure safe operation. These require-
ments add considerable complexity to the development process
and in particular require regular review especially when a new
version of the app becomes available. cloudUPDRS received
medical device status in the UK in May 2016.
VI. LEARNING TEST MOVEMENTS
In Section IV-A we show how to extend standard lab-
based practice for the precise measurement of motor symptoms
in PD using a smartphone. In this setting, assessments are
supervised by a qualified practitioner who, in addition to
helping operate the equipment, can ensure that patients follow
closely the actions dictated by Part III of the MDS-UPDRS
protocol. However, in the case of self-assessment at home
using cloudUPDRS supervision by an expert is unavailable. To
address this lack of expert supervision we have designed the
guided user experience presented in Section IV, which aims to
educate the patient and steer them through the process. While
this approach has produced positive results, full compliance
with the prescribed actions still cannot be guaranteed or
confirmed. Hence, it is necessary that cloudUPDRS provides
a mechanism though which data quality can be verified. In
particular, it is imperative to introduce a means by which it
becomes possible to confirm that the recordings submitted
have been captured while the patient performs the required
actions correctly3. Failure to do so would produce bio-signal
measurements that are not representative of the intended
tremor type and are likely to result in erroneous scoring.
To achieve this goal, we augment the user experience
presented by the app with a deep learning methodology [44].
This approach enables the cloudUPDRS system to learn tremor
features associated with a high quality signal and alert the user
when an observation has not been captured under satisfactory
circumstances. Enabled by recent advances in general-purpose
computing using graphics processing units and related algo-
rithmic developments, this methodological approach employs
multiple hidden layers to obtain notable results permitting
neural networks to identify preferred features directly from
the data. This feature of the selected methodology appears es-
pecially pertinent to the data quality issue under consideration.
The data set used to investigate the performance of this
approach is taken from the first cohort of patients enrolled in
the cloudUPDRS trials (8 male and 4 female). Specifically, we
consider 227 distinct test sessions conducted over a period of
three months (June to August 2016). Data was collected from
9 different phone models providing acceleration measurements
at least with a minimum sampling rate of 50Hz, implemented
using the data collection code base of the cloudUPDRS app
(other source code elements not affecting data collection were
modified during this period). Results are reported specifically
for pronation-supination observations of the right hand, with-
out loss of generality for the purposes of this paper. Data
captured by the app are normalised but no other pre-processing
is performed at this stage.
A. Rationale and Overview
To formulate an algorithmic solution, we reframe the prob-
lem of captured data verification as one of binary classification.
3In the case of the one- and two-finger tapping tests it is relatively
straightforward to identify when the process has been followed accurately
directly from the output of the bio-signal processing of Section IV-A.
Specifically, the goal of the verification task is to discriminate
between high-quality observations and lower-quality sensor
recordings captured during movements that do not closely
adhere to the guidance of the MDS-UPDRS protocol. To this
end, we employ a training data set of observations representing
both acceptable and unsuitable cases with known data quality
characteristics, guaranteed by the fact that they are collected
by the app under controlled conditions or inspected manually.
From this data set, features that are distinct within each
class are identified algorithmically. Subsequently, the obtained
representations are employed to test new observation data
submitted by patients via the app: Submissions classified as
offering adequate quality are forwarded to the appropriate mi-
croservices for data ingestion and signal processing, otherwise
they are rejected and excluded from further consideration.
This methodology can be applied asynchronously as part
of the data pre-processing and quality assurance phase or
interactively, incorporated in the cloudUPDRS app. The latter
is possible due to the fact that the classification process has
two distinct stages: an initial model training phase representing
the most computationally intensive task followed by a sample
assessment phase which is relatively lightweight for modern
smartphone hardware. As such, the model can be constructed
off-line using archival observation data for training and later
incorporated in the app, which can conduct real-time quality
assessments at the time of data recording and interactively
request the repeat of specific individual observations as ap-
propriate to ensure that all submitted tests are usable.
B. Data Segmentation and Pre-processing
Because the duration of each individual observation in
cloudUPDRS is 60 seconds and depending on the actual sam-
pling rate supported by the phone used for measurement, the
number of samples captured can be relatively very high. For
example, sampling at 50Hz results to data traces consisting
of over 3, 000 records. Rather than incurring the prohibitively
excessive computational cost of processing the full sample as
a single input we opt to segment the raw signal and consider
individual sections separately. For the current investigation and
to facilitate manual labelling of the samples we opt to extract
the mid-section of the signal. Considering sample sizes of
length 256 and 512 respectively, we generate two data sets
which we refer to in the following paragaphs as mid-256 and
mid-512. As part of this pre-processign step, measurements
along the three axes of acceleration expressed in the device
coordinate system are supplemented with an extra feature
recording the magnitude of acceleration m in Euclidean space.
C. Neural Network Architecture
The core ingredient of our approach is provided by Feed
Forward Artificial Neural Networks (FFANN) trained in su-
pervised mode [52]. FFANNs use layers of interconnected
neurons represented as matrices of real valued numbers cor-
responding to connection strengths between the neurons. At
each layer neurons perform simple computations, integrating
inputs received from neurons at the preceding layer and
transforming the signal through activation functions that help
regularize data. A geometric interpretation of this process is
that activation functions enable FFANNs to partition the high-
dimensional data space on which they operate.
This computational model is referred to as the Multilayer
Perceptron (MLP) and we will use the term Deep Multilayer
Perceptron (DMLP) to refer to the proposed architecture from
this point onwards, as it employs five hidden layers whilst
the maximum number typically used by simple MLPs is two.
In addition, MLPs traditionally employ the sigmoid and tanh
activation functions because they offer good performance with
smaller to medium sized networks. For the DMLP model
developed for cloudUPDRS, ReLU or softplus are preferred
instead. This is due to the fact that the latter activation
functions can mitigate the vanishing gradient problem which
affects deep networks. The function enables them to obtain
sparse representations by hard-limiting the input of negative
hidden nodes to zero [33].
For learning to happen, the output yˆ of the constructed
network must be compared against the desired output y, which
in the cloudUPDRS case represents the appropriate quality
class label that the network should produce, that is, accept or
reject the sample. This information is used with a so-called
cost or objective function which the DMLP aims to minimise.
Here we adopt categorical cross-entropy L as the objective
function, defined as L(y, yˆ) = −y log yˆ − (1− y) log(1− yˆ).
The final step in the process is the application of the
backpropagation algorithm [47] which enables the network to
learn the distribution that generated the training data. Back-
propagation employs the chain rule to calculate the derivatives
of the error produced by the objective function with respect
to each connection strength between neurons, which are then
used to update it. Different versions of the algorithm have been
proposed in the literature and in this case we adopt Adam [21],
a stochastic optimisation variant.
The standard approach for training MLPs is to feed a
single pattern at each step in a stochastic fashion, a process
known as Stochastic Gradient Descent (SGD) in the case of
the backpropagation algorithm. Although very popular and
effective, standard SGD is not preferred with DMLPs mainly
due to the prolonged calcualtions required to update the DMLP
weights for each pattern in the data set. In cloudUPDRS we
adopt instead the mini-batch SGD alternative, where data is
fed in small batches and the error averaged out so that only
one error signal is propagated for each batch.
To validate the effectiveness of the cloudUPDRS approach
we compare its performance against several well-established
alternatives selected for their recent success in industrial
systems or in highly-regarded competitions such as Kaggle.
Full details are provided in Section VI-E below.
D. Classifier Training
Training is carried out separately for each acceleration axis
and for the magnitude of acceleration as described in Sec-
tion VI-B and for each of the mid-256 and mid-512 data sets.
Separate training is preferable in this case because it ensures
Fig. 2. Average classification success rate for the mid-256 data set.
that each feature is captured accurately and its predictive
power can be evaluated independently. Further, the so-called
leave-one-out method [1] is combined with early stopping to
facilitate the full exploitation of the data set available during
training and to reduce the risk of overfitting. The choice of this
approach reflects the fact that the data set under investigation
has 227 data points which is relatively low in this context.
Each iteration of leave-one-out process involves the exclu-
sion of a single pattern from the full data set, training the
classifier on the remaining patterns and testing on the pattern
omitted. Consequently the DMLP of Section VI-C is trained
as many times as the points available in the data set, in this
case 227 times. One limitation of this technique is that it can
become biased on the weight initialisation. To address this the
process is repeated ten times using different initial random
weights and the mean is used as the overall performance met-
ric. Thus, the experiments summarised below are conducted
using ten cycles of leave-one-out cross-validation per feature,
so that 2, 270 classifiers have been trained and averaged for
each of the four features and for each of the data sets.
The early stopping heuristic applied ensures that the learn-
ing process is terminated when it reaches a certain predefined
threshold. Specifically, we employ three criteria: (i) the cate-
gorical cross-entropy or else training error falls below 0.001;
(ii) training classification success reaches 100%; or, (iii) the
learning process has executed 500 iterations. The benefit of
using early stopping is that it prevents the DMLP classifier
from memorising counter-productive characteristics discov-
ered in certain samples, especially when these are spurious
or irrelevant for the accurate determination of high versus low
quality observations. This technique works well when used in
conjunction to leave-one-out as it ensures that the DMLP is
not over trained [32] on any part of the data set.
E. Results
The deep learning approach described in Sections VI-C and
VI-D is implemented using Keras (cf. https://keras.io) to
provide the description of the DMLP model, on top of the
computational graph engine theano (cf. http://deeplearning.
net/software/theano/). Training was carried out on an array
of NVIDIA K40 GPUs achieving a 20-fold speedup against a
standard multicore CPU. To provide a baseline against which
to evaluate our approach we compare its performance with the
following classifiers implemented using the scikit-learn
Fig. 3. Average classification success rate for the mid-512 data set.
TABLE II
CONFUSION MATRIX FOR DMLP CLASSIFICATION FOR THE MID-256 AND
MID-512 DATA SETS (AVERAGED PERFORMANCE). LABELS: T/F
TRUE/FALSE AND P/N POSITIVE/NEGATIVE. A REPRESENTS THE
AVERAGE OF ALL FEATURES.
mid-256 data set
TP (%) FN (%) TN (%) FP (%)
M 124.9 88.0 17.1 12.0 56.7 66.7 28.3 33.3
X 142.6 92.6 11.4 7.4 45.5 62.3 27.5 37.7
Y 165.1 95.4 7.9 4.6 32.1 59.4 21.9 40.6
Z 168.2 94.0 10.8 6.0 27.1 56.5 20.9 43.5
A 150.2 92.5 11.8 7.5 40.4 61.2 24.6 38.8
mid-512 data set
TP (%) FN (%) TN (%) FP (%)
M 122.4 86.2 19.6 13.8 50.1 58.9 34.9 41.1
X 138.1 89.7 15.9 10.3 37.6 51.5 35.4 48.5
Y 164.3 95.0 8.7 5.0 24.5 45.4 29.5 54.6
Z 165.5 92.5 13.5 7.5 21.0 43.8 27.0 56.2
A 147.6 90.8 14.4 9.2 33.3 49.9 31.7 50.1
[38] machine learning library: (i) Gaussian Naive Bayes [36];
(ii) Bernoulli Naive Bayes [36]; (iii) Random Forest Classifier
[7] which employs an ensemble of random decision trees
each selected from a sample drawn with replacement; (iv)
Extra Trees Classifier [13] is a variation of random forest
with thresholds randomly drawn for each candidate feature;
(v) AdaBoost Classifier [53] is a meta-estimator which adjusts
classifier weights so as to improve learning from difficult
classes; (vi) Bagging Classifier [6] is also a meta-estimator
which operates on random subsets of the training data to
reach a final prediction by aggregating their results; and (vii)
Gradient Boosting Classifier [12] which performs optimization
of arbitrary differentiable loss functions.
Classification results calculated for all features of the mid-
256 data set following the methodology outlined in Section
VI-C after training as detailed in Section VI-D are compared
to the baseline classifiers in Figure 2. Our methodology
employing the DMLP classifier, denoted as Neural Net in the
figure, provides the best performance across all features. Note
in particular that the magnitude of the standard deviation is
very low indicating that initialisation bias has been avoided.
Results for the mid-512 data set are calculated following the
same approach and summarised in Figure 3. Also in this case,
the DMLP approach outperforms all alternative classifiers
across all features, often by a significant margin.
Further, the confusion matrix for the DMLP classifier is
computed and presented in Table II. Note that the percentage
of false negatives (FN) for the mid-256 data set when all
features have been considered is approximately 7% which
represents good performance, while false positives (FP) re-
main below 39%. Hence, the DMLP approach developed for
cloudUPDRS identifies correctly the vast majority of low
quality samples and causes relatively limited unnecessary
repetition of recordings.
VII. DEVELOPING THE CLOUDUPDRS QUICK TEST
In this section, we turn our attention to the development
of methods that achieve significant reductions in test duration
so as to enable patients to use cloudUPDRS on a daily basis.
As suggested by the user studies summarised in Section III,
the majority of patients identified a maximum of 5 minutes as
the desirable duration for the test. However, even after the
initial familiarisation period the full implementation of the
procedure typically requires 25 minutes, an estimate that has
been confirmed from system logs and independently through
user feedback. The critical influence of test duration on user
adoption rates was further confirmed during the initial three
months of field testing. While the majority of participants
carried out tests regularly during the first week following
the commission of the app, compliance rates dropped sharply
by the end of the third week, and only one out of the 12
participants continued to carry out tests at the end of the three-
month testing period.
A. Test Duration and Characteristics
Recall from Section IV, that according to the MDS-UPDRS
protocol each individual observation requires 60 seconds of
recording and the full test consists of 17 observations, in ad-
dition to the medication and well-being questionnaire. Clearly,
to reduce the overall duration of the test there are two main
options namely to shorten the recording time for individual
observations or to reduce the number of observations carried
out by selecting a subgroup of the full 17-item set. The final
questionnaire requires approximately 30 seconds and is always
required because it is used to track medication.
First, consider the option to reduce the length of individual
observations without loss of precision in the estimation of
motor performance. Specifically, we investigate whether the
60 second observation period set by the MDS-UPDRS protocol
is necessary or instead consistent scoring can be still main-
tained after significantly reducing its duration. To this end,
we conduct observations of motor performance for alternative
recording periods of 20 and 40 seconds and compare these
against measurements carried out for the the full 60 seconds.
Tremor and bradykinesia performance metrics were calculated
for all observation types in our test data set consisting of
133 full tests carried out by 35 different individuals. In the
remainder of this section we report scores calculated for tremor
power at rest for the right hand, without loss of generality and
so as to specifically quantify our findings.
Figure 4 summarises the results of this analysis and demon-
strates that for the majority of patients a shorter observation
Fig. 4. Change in recorded tremor power between tests of 60 and 20 seconds.
period results in a significant change of their reported mo-
tor performance. Specifically, Figure 4 shows that when the
recording period is reduced from 60 to 20 seconds the power
of the tremor for 60% of the patients is reduced by more
than 10%. Similar results are obtained when the observation
length is reduced to 40 seconds with the same magnitude of
change observed for 35% of the participants in this case. These
changes in motor performance for shorter recording periods
correspond to significant changes in the estimated MDS-UPDRS
score for a single observation ranging between 1 and 2.5
points on the MDS-UPDRS scale. This difference in the actual
clinical score corresponds to an average expected disease
progression over a six- and twelve-month period respectively,
thus representing a significant error in precisely assessing
motor performance.
These results clearly imply that that it is necessary to main-
tain the full 60 second recording period for each individual
observation. Relevant clinical literature considering the MDS-
UPDRS does not appear to offer explicit justification for this
performance. However, it seems that this is an observation
readily confirmed by experienced clinicians such as those
participating in focus groups conducted by cloudUPDRS (cf.
Section III). In particular, it was suggested that the longer
duration is required in most cases to cause mild fatigue that
reveals the true characteristics of motor performance. In any
case, the option to develop the quick test by reducing the
duration of individual observations does not appear viable and
alternatives must be considered.
B. Identifying Clinically Distinct Factors
Clinical investigations of the MDS-UPDRS scale reported
in the medical literature have identified a smaller group of
clinically distinct factors, typically five to six, that provide
high correlation to the overall score of the motor examination
of Part III of the MDS-UPDRS [45], [46]. This observation
corroborates the possibility to develop the quick test by
reducing the number of individual observations to a much
restricted group, which correlates well with the overall patient
score. Furthermore, note that the MDS-UPDRS protocol was
designed to explore exhaustively the full range of possible
motor symptoms caused by PD, but a specific individual would
typically present a smaller number of symptoms (especially
in earlier stages of PD) that dominate their MDS-UPDRS
score and that remain relatively stable over a time frame
of a few months. Indeed, a common observation is that PD
motor symptoms are asymmetric [5], [40] for example, for
a particular patient one side can be significantly affected by
tremor while the opposite side may not be affected at all thus
contributing zero units towards their MDS-UPDRS score.
Motivated by this observation, we develop a methodology
using standard machine learning methods that successfully
identify the appropriate subgroup of observations for a specific
patient which offer the highest predictive power of their overall
motor performance. Upon enrolment in cloudUPDRS, patients
are required to carry out the full test at least five times during
the first week of monitoring. At the end of this calibration
period we use the data of the full test to conduct a feature
importance analysis. Specifically, following [13] we apply
an ensemble of randomized decision trees on multiple sub-
samples of the test data improving its predictive accuracy
through averaging and over-fitting control. We then rank
individual observations according to the relative importance
of their corresponding features (two and three features per
tremor and bradykinesia test respectively). Finally, we select
the subgroup of top performing observations which account
for at least 80% of the variance in the overall UPDRS score.
At the end of this process, the cloudUPDRS system is con-
figured with an individual user profile detailing the subgroup
of observations identifed for inclusion in the quick test. This
profile is automatically communicated to the app at the next
start up so that it is reconfigured to enable the quick test feature
in its home screen (cf. Figure 1). The selected settings remain
active for a period of six months after which a new set of
full tests is required due to the likelihood of changes in motor
symptoms over this time frame.
C. Results
To evaluate the effectiveness of this approach we employed
the data set described in Section VII-A selecting only patients
for which at least five full test results are available. For
each patient we apply the above methodology to create a
personalised quick test profile. We discover that in all cases
we are able to account for the target variance using features
associated with only three or less observations. This result is
consistent across all patients examined representing medium
and progressed stages of the disease.
Figure 5 shows the results of this analysis for a typical
patient from this cohort suggesting in this case that just three
observations (from which seven features are calculated) are
adequate to account for approximately 90% of the varia-
tion. Specifically, this patient’s quick test profile consists of
observations of left leg agility, right arm rest tremor and
single tapping of the left hand which provide the adequate
information to track their overall motor performance. System
logs confirm that this patient was able to complete the quick
tests consistently in less than 4 minutes over 50 times in the
two months following the availability of their profile. Note that
Fig. 5. Predictive power of features associated with individual UPDRS
observations.
this patient is at an advanced stage of PD presenting significant
mobility impairments.
VIII. CONCLUSION
According to the World Health Organization [51], ageing
populations generate considerable economic effects, notably
intensifying pressures on health-care systems which for many
of the more economically developed countries already repre-
sent the largest area of expenditure. In the UK, the cost of
caring for PD patients exceeds 1.25 billion British pounds
annually and is rapidly increasing. In this socioeconomic
situation, mobile health apps present a unique opportunity for
the provision of cost effective care at population scale. Yet, to
reach their full potential such apps must offer safety guarantees
and facilitate a seamless user experience.
In this paper, we introduced two novel techniques developed
for cloudUPDRS, a medical device app for the assessment of
motor symptoms of PD at home, addressing these require-
ments. First, a bespoke deep learning approach was employed
to replace expert human supervision of the administration
of the common motor performance assessment protocol for
PD; and second, a personalised quick test was developed to
accurately trace overall motor performance while considerably
improving patient compliance. In our experiments both ap-
proaches performed reliably and produced promising results.
We anticipate both techniques to be useful for a wider class
of mobile health-care apps with similar requirements. Further
experimentation with a larger patient population is of course
necessary to fully assess the potential of the two techniques
developed and we are currently working towards this within
the CUSSP clinical study.
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